Lophius Biosciences Closes Financing Round and Expands Management Board
Complete the form below to unlock access to ALL audio articles.
Lophius Biosciences announced the closing of a further financing round. With VRD GmbH and WIC GmbH two new investors will financially support the company alongside existing investors such as S-Refit, HighTech Gründerfonds (HTGF), Bayern Kapital and two Business Angels. With a commitment of about 4 Mio. EUR, Lophius Biosciences intends to fully introduce its technologies and products in the field of T-cell based diagnostics. Prof. Dr. Ralf Wagner, former CEO of GeneArt AG, has been appointed as Managing Director in order to drive the further development of the company together with the current Managing Director Dr. Michael Lutz.
Prof. Wagner was founder, CEO and CSO of Regensburg-based company GeneArt AG which specialized in the field of synthetic biology. Following the acquisition by Life Technologies in 2010 he was responsible as Site leader and Vice President Synthetic Biology for the successful integration of GeneArt AG into Life Technologies. As professor for molecular microbiology and gene therapy, Dr Wagner is also member of the Medical faculty at the University of Regensburg.
„We are very pleased that the positive development of Lophius Biosciences could be continued and even accelerated with these new funds. With their commitment, the new and existing investors have strongly validated the (recent) successful product developments for the CE-marked T-Track© CMV and EBV-Tests and T-Track© TB (Tuberculosis) based on our two patented technology platforms” said Dr. Michael Lutz, Managing Director of Lophius Biosciences.
Prof. Wagner’s strong focus will be on the successful rounding off and launch of the product portfolio together with Dr. Lutz and the whole Lophius Biosciences team. “Lophius Biosciences is a young but very innovative biotech company with the potential to become a fully integrated player in the new field of T-cell based diagnostics. Based on its proprietary know-how the company has many unique selling points for its products to provide significant diagnostic and clinical value to patients and physicians in a number of medical indications. I am happy to become part of this very interesting opportunity”, added Prof. Wagner.
„Together with the expanded management the existing investors highly welcome both VRD GmbH and WIC GmbH as new investors who strongly support the current company and investor strategy. With the addition of Prof. Wagner to the management board, the company has clearly accomplished another key milestone. Prof. Wagner and the existing Managing Director Dr. Lutz will form a strong team with outstanding expertise for developing small and medium-sized companies“, added Mr. Bertram Gilka-Bötzow, Head of Lophius Biosciences´ Advisory Board and Investment Director of S-Refit, the current Lead Investor of Lophius Biosciences.
